• Combining Lymphoma Molecular Profiles, Microenvironment Signatures May Improve Prognosis

    A research collaboration between biomedical software startup BostonGene and Weill Cornell Medicine has found that the tumor microenvironment influences the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), suggesting that genomics alone may not provide a complete picture of a patient’s disease trajectory. Read More
  • genomeweb

    BostonGene Partners With NIH on Clonal Evolution Study

    BostonGene today announced a partnership with the National Institutes of Health to offer molecular profiling and therapy recommendations in a cancer study. Read More
  • BostInno

    BostonGene Has Big Plans for Treating Cancer With Precision Medicine

    Biomedical software startup BostonGene is refreshed and ready to take on the world of cancer treatment. Read More
  • genomeweb

    BostonGene Eyes Precision Oncology as it Emerges from Stealth

    BostonGene plans to commercialize its technology for selecting the best therapies for cancer patients. Read More
  • BostonGene raises $50M to improve cancer treatment with AI and cutting-edge research

    Read More